Keros Therapeutics, Inc. (KROS) Tops Q3 EPS by 2c

Keros Therapeutics, Inc. (NASDAQ: KROS) reported Q3 EPS of ($1.33), $0.02 better than the analyst estimate of ($1.35). Revenue for the quarter came in at $8 thousand.

For earnings history and earnings-related data on Keros Therapeutics, Inc. (KROS) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Union Pacific (UNP) Reiterated at Market Outperform by Citizens - Most Attractive in Rail Group
• Worthington Industries (WOR) Tops Q1 EPS by 7c